首页 > 最新文献

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique最新文献

英文 中文
Erratum to "Voice quality after surgery or radiotherapy for glottic T1 squamous cell carcinoma: Results of the VOQUAL study" [Cancer Radiother. 28 (2024) 373-379]. 声门 T1 鳞状细胞癌手术或放疗后的嗓音质量:28 (2024) 373-379] 的勘误。
Pub Date : 2024-10-29 DOI: 10.1016/j.canrad.2024.09.001
L Jan, J Labreuche, X Liem, B Rysman, M Morisse, G Mortuaire, F Mouawad
{"title":"Erratum to \"Voice quality after surgery or radiotherapy for glottic T1 squamous cell carcinoma: Results of the VOQUAL study\" [Cancer Radiother. 28 (2024) 373-379].","authors":"L Jan, J Labreuche, X Liem, B Rysman, M Morisse, G Mortuaire, F Mouawad","doi":"10.1016/j.canrad.2024.09.001","DOIUrl":"https://doi.org/10.1016/j.canrad.2024.09.001","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Short- and medium-term tolerance of hypofractionated prostate radiotherapy with simultaneous integrated boost]. [前列腺低分次同步综合增强放疗的短期和中期耐受性]。
Pub Date : 2024-08-23 DOI: 10.1016/j.canrad.2024.04.004
Laurène Larrivière, Stephane Supiot, Astrid Thomin, Simon Jan, Sofia Bakkar, Gilles Calais

Purpose: This retrospective study was conducted to ensure that irradiation of the pelvic lymph node areas associated with simultaneous hypofractionated boost to the prostate according to the protocol implemented at the university hospital of Tours (France) does not result in excess urinary and digestive toxicity in the short and medium term.

Materials and methods: The study population included patients with localized unfavourable intermediate or high-risk prostate cancer. The dose delivered was 65Gy in 25 fractions of 2.6Gy to the prostate and seminal vesicles, and 50Gy in 25 fractions of 2Gy to the pelvic lymph nodes. Acute toxicity events (between the start of radiotherapy and the first follow-up consultation) and medium-term toxicity events (after the first follow-up consultation) were assessed using the CTCAE version 5.0 classification.

Results: Sixty-three patients were treated according to the protocol between January 1st, 2020, and October 31st, 2022. The majority of them had high-risk prostate cancer (79%). The median follow-up was 15 months. Very few patients reported grade 3-4 toxicity acutely (6% urinary and 0% digestive toxicity) or in the medium term (7% urinary and 0% and digestive toxicity).

Conclusion: Radiotherapy of pelvic lymph node areas with simultaneous hypofractionated boost to the prostate is feasible, with low rates of severe acute and medium-term toxicity.

目的:本项回顾性研究旨在确保根据图尔大学医院(法国)实施的方案对盆腔淋巴结区域进行照射并同时对前列腺进行低分量照射不会在中短期内导致过多的泌尿和消化系统毒性:研究对象包括局部不理想的中度或高度危险前列腺癌患者。前列腺和精囊的放射剂量为 65Gy,25 次分次放射,每次 2.6Gy;盆腔淋巴结的放射剂量为 50Gy,25 次分次放射,每次 2Gy。急性毒性事件(放疗开始至首次复诊期间)和中期毒性事件(首次复诊后)采用 CTCAE 5.0 版分类进行评估:在2020年1月1日至2022年10月31日期间,63名患者按照方案接受了治疗。其中大多数患者患有高风险前列腺癌(79%)。中位随访时间为 15 个月。极少数患者报告了3-4级急性毒性(6%为泌尿系统毒性,0%为消化系统毒性)或中期毒性(7%为泌尿系统毒性,0%为消化系统毒性):结论:对盆腔淋巴结区进行放疗,同时对前列腺进行低分次照射是可行的,急性和中期严重毒性发生率较低。
{"title":"[Short- and medium-term tolerance of hypofractionated prostate radiotherapy with simultaneous integrated boost].","authors":"Laurène Larrivière, Stephane Supiot, Astrid Thomin, Simon Jan, Sofia Bakkar, Gilles Calais","doi":"10.1016/j.canrad.2024.04.004","DOIUrl":"https://doi.org/10.1016/j.canrad.2024.04.004","url":null,"abstract":"<p><strong>Purpose: </strong>This retrospective study was conducted to ensure that irradiation of the pelvic lymph node areas associated with simultaneous hypofractionated boost to the prostate according to the protocol implemented at the university hospital of Tours (France) does not result in excess urinary and digestive toxicity in the short and medium term.</p><p><strong>Materials and methods: </strong>The study population included patients with localized unfavourable intermediate or high-risk prostate cancer. The dose delivered was 65Gy in 25 fractions of 2.6Gy to the prostate and seminal vesicles, and 50Gy in 25 fractions of 2Gy to the pelvic lymph nodes. Acute toxicity events (between the start of radiotherapy and the first follow-up consultation) and medium-term toxicity events (after the first follow-up consultation) were assessed using the CTCAE version 5.0 classification.</p><p><strong>Results: </strong>Sixty-three patients were treated according to the protocol between January 1st, 2020, and October 31st, 2022. The majority of them had high-risk prostate cancer (79%). The median follow-up was 15 months. Very few patients reported grade 3-4 toxicity acutely (6% urinary and 0% digestive toxicity) or in the medium term (7% urinary and 0% and digestive toxicity).</p><p><strong>Conclusion: </strong>Radiotherapy of pelvic lymph node areas with simultaneous hypofractionated boost to the prostate is feasible, with low rates of severe acute and medium-term toxicity.</p>","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142057584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of adjuvant lymph node field radiotherapy and immunotherapy for stage III melanoma. III期黑色素瘤淋巴结野外放疗和免疫疗法的辅助治疗效果。
Pub Date : 2024-08-21 DOI: 10.1016/j.canrad.2024.03.006
L Marxgut, A Desagneaux, A Bellier, S Mouret, J Charles, M Laramas, C Verry

Purpose: With the promising results of immunotherapy in patients with stage III melanoma, the role of adjuvant radiotherapy after resection and complete lymph-node dissection must be reassessed. We evaluate the outcomes and safety of adjuvant radiotherapy and immunotherapy compared to immunotherapy only in patients with resected stage III melanoma.

Patients and methods: This retrospective and single institution study included patients treated for a stage III melanoma with complete lymph-node dissection and adjuvant immunotherapy from January 2019 to December 2022. The radiotherapy associated with immunotherapy group was defined by completion of immunotherapy and adjuvant radiotherapy in the lymph-node dissection area. The primary endpoint was disease-free survival. The secondary endpoints were locoregional progression, incidence of adverse events grade 3 or above and disease-free survival rate in patients with high risk of locoregional recurrence.

Results: Thirty-three patients were included. Among them, twelve received adjuvant lymph-node field radiotherapy. The median duration of follow-up was 17months (range: 8-45months). Patients receiving radiotherapy and immunotherapy had a significantly higher disease stage and more frequent extracapsular extension. At 12months, the disease-free survival rate was 66.7% for the patients receiving immunotherapy alone (95% CI: 42.5-82.5%) and 83.3% for those receiving radiotherapy and immunotherapy (95% CI: 48.2-95.6%; P=0.131). The locoregional progression rate was 24% in patients receiving immunotherapy and 8% in patients receiving immunotherapy and radiotherapy (P=0.379). After adjuvant treatment, 6% of patients developed grade 3 or above immunotherapy-related events and none developed grade 3 or above radiation-related adverse events.

Conclusion: In patients with stage III melanoma, adjuvant lymph-node field radiotherapy combined with immunotherapy seems to be associated with longer disease-free survival, with acceptable tolerance. However, these results need to be confirmed by long-term and prospective studies.

目的:随着免疫疗法在III期黑色素瘤患者中取得良好疗效,必须重新评估切除术和完全淋巴结清扫术后辅助放疗的作用。我们对已切除的III期黑色素瘤患者接受辅助放疗和免疫治疗与仅接受免疫治疗的结果和安全性进行了评估:这项回顾性单机构研究纳入了2019年1月至2022年12月期间接受完全淋巴结清扫和辅助免疫治疗的III期黑色素瘤患者。在淋巴结清扫区域完成免疫治疗和辅助放疗的患者被定义为放疗联合免疫治疗组。主要终点是无病生存期。次要终点为局部进展、3级或以上不良反应发生率以及局部复发风险高的患者的无病生存率:共纳入 33 名患者。结果:共纳入 33 例患者,其中 12 例接受了淋巴结野辅助放疗。中位随访时间为 17 个月(8-45 个月)。接受放疗和免疫疗法的患者的疾病分期明显较高,囊外扩展也更为常见。12个月时,单独接受免疫疗法的患者无病生存率为66.7%(95% CI:42.5-82.5%),接受放疗和免疫疗法的患者无病生存率为83.3%(95% CI:48.2-95.6%;P=0.131)。接受免疫疗法的患者局部进展率为24%,接受免疫疗法和放疗的患者局部进展率为8%(P=0.379)。辅助治疗后,6%的患者出现了3级或以上免疫治疗相关事件,没有患者出现3级或以上放疗相关不良事件:结论:在III期黑色素瘤患者中,淋巴结野辅助放疗联合免疫治疗似乎能延长无病生存期,且耐受性可接受。然而,这些结果还需要长期和前瞻性研究来证实。
{"title":"Outcomes of adjuvant lymph node field radiotherapy and immunotherapy for stage III melanoma.","authors":"L Marxgut, A Desagneaux, A Bellier, S Mouret, J Charles, M Laramas, C Verry","doi":"10.1016/j.canrad.2024.03.006","DOIUrl":"https://doi.org/10.1016/j.canrad.2024.03.006","url":null,"abstract":"<p><strong>Purpose: </strong>With the promising results of immunotherapy in patients with stage III melanoma, the role of adjuvant radiotherapy after resection and complete lymph-node dissection must be reassessed. We evaluate the outcomes and safety of adjuvant radiotherapy and immunotherapy compared to immunotherapy only in patients with resected stage III melanoma.</p><p><strong>Patients and methods: </strong>This retrospective and single institution study included patients treated for a stage III melanoma with complete lymph-node dissection and adjuvant immunotherapy from January 2019 to December 2022. The radiotherapy associated with immunotherapy group was defined by completion of immunotherapy and adjuvant radiotherapy in the lymph-node dissection area. The primary endpoint was disease-free survival. The secondary endpoints were locoregional progression, incidence of adverse events grade 3 or above and disease-free survival rate in patients with high risk of locoregional recurrence.</p><p><strong>Results: </strong>Thirty-three patients were included. Among them, twelve received adjuvant lymph-node field radiotherapy. The median duration of follow-up was 17months (range: 8-45months). Patients receiving radiotherapy and immunotherapy had a significantly higher disease stage and more frequent extracapsular extension. At 12months, the disease-free survival rate was 66.7% for the patients receiving immunotherapy alone (95% CI: 42.5-82.5%) and 83.3% for those receiving radiotherapy and immunotherapy (95% CI: 48.2-95.6%; P=0.131). The locoregional progression rate was 24% in patients receiving immunotherapy and 8% in patients receiving immunotherapy and radiotherapy (P=0.379). After adjuvant treatment, 6% of patients developed grade 3 or above immunotherapy-related events and none developed grade 3 or above radiation-related adverse events.</p><p><strong>Conclusion: </strong>In patients with stage III melanoma, adjuvant lymph-node field radiotherapy combined with immunotherapy seems to be associated with longer disease-free survival, with acceptable tolerance. However, these results need to be confirmed by long-term and prospective studies.</p>","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142038009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pattern of relapse following three-field lymphadenectomy of esophageal carcinoma and related factors predictive of recurrence 食管癌三野淋巴结切除术后复发模式及预测复发的相关因素
Pub Date : 2022-06-21 DOI: 10.1101/2022.06.20.22276551
Z. Xu
Background: For treatment of esophageal carcinoma, the optimal postoperative radiotherapy target volume after three-field lymph node dissection(3-FLD) had not been determined. We analyzed local recurrence pattern of thoracic esophageal carcinoma and risk factors of lymph node recurrence after 3-FLD without prophylactic radiotherapy. Methods: We reviewed 1282 patients with thoracic esophageal squamous cell carcinoma(ESCC) who were treated with 3-FLD without radiotherapy from 2010 to 2018 and analysed local recurrence patterns and risk factors of lymph node recurrence, in order to provide a reference for determination of the radiotherapy target volume for thoracic ESCC. Results: The lymph node recurrence accounted for 91.0% of treatment failures. The mediastinal, cervical and abdominal lymph node recurrence rates were 85.2%, 36.5% and 22.4%, respectively,(x 2 =264.596, P=0.000). The superior, middle and inferior mediastinal lymph node recurrence rates were 67.54%, 27.87% and 0.98%, respectively(x 2 =313.600, P=0.000). In a multivariate analysis, Cevical metastases were significantly associated with N stage and Preoperative cevical lymph node status. Abdominal metastases were significantly associated with the number of preoperative abdominal lymph node metastases( LNM), tumor location and N stage. Conclusions: The main pattern of local-regional recurrence might be lymph node metastasis after radical 3-FLD without radiotherapy in esophageal carcinoma. The dangerous lymph node recurrence regions included neck, superior and middle mediastinum. Radiologist might took the number of pre-operative abdominal lymph nodes and tumor location into consideration while delineating the target area of abdominal region .
背景:对于食管癌的治疗,术后三野淋巴结清扫(3-FLD)的最佳放疗靶体积尚未确定。我们分析了胸段食管癌3-FLD术后未进行预防性放疗的局部复发类型及淋巴结复发的危险因素。方法:回顾性分析2010 - 2018年1282例经3-FLD非放疗治疗的胸段食管鳞状细胞癌(ESCC)患者,分析其局部复发类型及淋巴结复发危险因素,为确定胸段食管鳞状细胞癌放疗靶量提供参考。结果:淋巴结复发占治疗失败的91.0%。纵隔、颈部、腹部淋巴结复发率分别为85.2%、36.5%、22.4% (χ 2 =264.596, P=0.000)。上、中、下纵隔淋巴结复发率分别为67.54%、27.87%、0.98% (χ 2 =313.600, P=0.000)。在一项多变量分析中,宫颈转移与N期和术前宫颈淋巴结状态显著相关。腹部转移与术前腹部淋巴结转移(LNM)数量、肿瘤位置和N分期显著相关。结论:食管癌未经放疗根治性3-FLD后局部复发可能以淋巴结转移为主。淋巴结复发危险区包括颈部、上纵隔和中纵隔。放射科医师在划定腹部靶区时,可能会考虑术前腹部淋巴结的数量和肿瘤的位置。
{"title":"Pattern of relapse following three-field lymphadenectomy of esophageal carcinoma and related factors predictive of recurrence","authors":"Z. Xu","doi":"10.1101/2022.06.20.22276551","DOIUrl":"https://doi.org/10.1101/2022.06.20.22276551","url":null,"abstract":"Background: For treatment of esophageal carcinoma, the optimal postoperative radiotherapy target volume after three-field lymph node dissection(3-FLD) had not been determined. We analyzed local recurrence pattern of thoracic esophageal carcinoma and risk factors of lymph node recurrence after 3-FLD without prophylactic radiotherapy. Methods: We reviewed 1282 patients with thoracic esophageal squamous cell carcinoma(ESCC) who were treated with 3-FLD without radiotherapy from 2010 to 2018 and analysed local recurrence patterns and risk factors of lymph node recurrence, in order to provide a reference for determination of the radiotherapy target volume for thoracic ESCC. Results: The lymph node recurrence accounted for 91.0% of treatment failures. The mediastinal, cervical and abdominal lymph node recurrence rates were 85.2%, 36.5% and 22.4%, respectively,(x 2 =264.596, P=0.000). The superior, middle and inferior mediastinal lymph node recurrence rates were 67.54%, 27.87% and 0.98%, respectively(x 2 =313.600, P=0.000). In a multivariate analysis, Cevical metastases were significantly associated with N stage and Preoperative cevical lymph node status. Abdominal metastases were significantly associated with the number of preoperative abdominal lymph node metastases( LNM), tumor location and N stage. Conclusions: The main pattern of local-regional recurrence might be lymph node metastasis after radical 3-FLD without radiotherapy in esophageal carcinoma. The dangerous lymph node recurrence regions included neck, superior and middle mediastinum. Radiologist might took the number of pre-operative abdominal lymph nodes and tumor location into consideration while delineating the target area of abdominal region .","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90169296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-dose salvage re-irradiation in recurrent/progressive adult diffuse gliomas: development of a novel prognostic scoring system. 复发/进展成人弥漫性胶质瘤的高剂量补救性再照射:一种新型预后评分系统的发展
Pub Date : 2022-06-01 DOI: 10.1016/j.canrad.2022.01.004
M. Maitre, T. Gupta, P. Maitre, Ayan Chatterjee, A. Dasgupta, A. Moiyadi, P. Shetty, S. Epari, A. Sahay, V. Patil, R. Krishnatry, G. Sastri, R. Jalali
{"title":"High-dose salvage re-irradiation in recurrent/progressive adult diffuse gliomas: development of a novel prognostic scoring system.","authors":"M. Maitre, T. Gupta, P. Maitre, Ayan Chatterjee, A. Dasgupta, A. Moiyadi, P. Shetty, S. Epari, A. Sahay, V. Patil, R. Krishnatry, G. Sastri, R. Jalali","doi":"10.1016/j.canrad.2022.01.004","DOIUrl":"https://doi.org/10.1016/j.canrad.2022.01.004","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"269-270 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72668015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
[Impact of NGS results on patient outcome with a multiform glioblastoma]. [NGS结果对多形式胶质母细胞瘤患者预后的影响]。
Pub Date : 2022-06-01 DOI: 10.1016/j.canrad.2022.01.002
M. Rom, R. Schott, E. Pencreac'h, H. Cebula, D. Cox, L. Bender, D. Antoni, B. Lhermitte, G. Noel
{"title":"[Impact of NGS results on patient outcome with a multiform glioblastoma].","authors":"M. Rom, R. Schott, E. Pencreac'h, H. Cebula, D. Cox, L. Bender, D. Antoni, B. Lhermitte, G. Noel","doi":"10.1016/j.canrad.2022.01.002","DOIUrl":"https://doi.org/10.1016/j.canrad.2022.01.002","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"6 4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83478540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative radiotherapy in prostate cancer: When and how? - An update review. 前列腺癌术后放疗:何时及如何?-更新回顾。
Pub Date : 2022-04-01 DOI: 10.1016/j.canrad.2021.10.009
R. Asso, Fabiana A M Degrande, J. L. Fernandes da Silva, E. Leite
{"title":"Postoperative radiotherapy in prostate cancer: When and how? - An update review.","authors":"R. Asso, Fabiana A M Degrande, J. L. Fernandes da Silva, E. Leite","doi":"10.1016/j.canrad.2021.10.009","DOIUrl":"https://doi.org/10.1016/j.canrad.2021.10.009","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82483287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Omentum flap as a spacer before carbon ion radiotherapy for gynecological recurrences. A technical note. 网膜瓣作为妇科复发碳离子放疗前的间隔剂。一个技术说明。
Pub Date : 2022-03-01 DOI: 10.1016/j.canrad.2021.12.009
A. Barcellini, A. Mirandola, M. R. Fiore, E. Orlandi, L. Cobianchi
{"title":"Omentum flap as a spacer before carbon ion radiotherapy for gynecological recurrences. A technical note.","authors":"A. Barcellini, A. Mirandola, M. R. Fiore, E. Orlandi, L. Cobianchi","doi":"10.1016/j.canrad.2021.12.009","DOIUrl":"https://doi.org/10.1016/j.canrad.2021.12.009","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"72 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74797756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[Role of tractography in stereotactic radiosurgery and brain stereotactic radiotherapy]. [导管造影在立体定向放射外科和脑立体定向放疗中的作用]。
Pub Date : 2022-03-01 DOI: 10.1016/j.canrad.2021.12.007
G. Dupic, C. Delmaire, J. Savatovsky, A. Kourilsky
{"title":"[Role of tractography in stereotactic radiosurgery and brain stereotactic radiotherapy].","authors":"G. Dupic, C. Delmaire, J. Savatovsky, A. Kourilsky","doi":"10.1016/j.canrad.2021.12.007","DOIUrl":"https://doi.org/10.1016/j.canrad.2021.12.007","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"165 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77212669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival impact of postoperative radiotherapy in patients with olfactory neuroblastoma: 513 cases from the SEER database. 嗅觉母细胞瘤术后放疗对患者生存的影响:来自SEER数据库的513例。
Pub Date : 2021-03-31 DOI: 10.21203/RS.3.RS-353943/V1
G. Duo, Jilong Feng, E. Zhang, Li-jun Wang
PUPOSETo evaluate the impact of postoperative radiotherapy (PORT) on survival in olfactory neuroblastoma (ONB) patients with different tumor staging.MATERIAL AND METHODSPatients with ONB were selected in the Surveillance, Epidemiology and End Results (SEER) database from 2004-2016. Survival analyses were performed using Kaplan-Meier (K-M) method, Cox regression analysis, and competing risk model.RESULTSA total of 513 patients were included in the study. Univariate and multivariate analysis results demonstrated that PORT was not an independent prognostic factor for overall survival (OS) of modified Kadish stage A and B patients (P=0.699 and P=0.248, respectively). Kadish stage C and D patients who underwent PORT had significantly better OS than those who did not undergo PORT (P=0.03 and P<0.0001). K-M curves revealed that the 5- and 10-year OS rates of patients who underwent PORT vs. non-PORT were 85.3% vs. 70.4% and 68.2% vs. 56.8% in stage C patients, respectively. For stage D patients, the 5-year OS rates were 70.7% and 42.6%, and 10-year OS rates were 53.4% and 29.5% in the PORT and non-PORT groups, respectively. The competitive risk model revealed that the 5-year cancer-specific cumulative mortality incidence decreased by 26.6% while the 10-year mortality incidence decreased by 41.4% in Kadish stage C patients who were treated using PORT; meanwhile, for Kadish stage D patients who were treated with PORT, the 5- and 10-year mortality incidences were reduced by 35.3% and 42.6%, respectively. Furthermore, we found that chemotherapy was not related to the prognosis of ONB patients (all P>0.05).CONCLUSIONOur results indicate that PORT improved survival outcomes of modified Kadish stage C and D ONB patients. However, PORT may not affect survival for modified Kadish stage A and B individuals. Chemotherapy was not recommended for ONB; therefore, further studies are warranted to determine its therapeutic significance.
目的探讨术后放疗(PORT)对不同肿瘤分期嗅觉神经母细胞瘤(ONB)患者生存的影响。材料与方法选择2004-2016年监测、流行病学和最终结果(SEER)数据库中ONB患者。生存率分析采用Kaplan-Meier (K-M)法、Cox回归分析和竞争风险模型。结果共纳入513例患者。单因素和多因素分析结果显示,PORT不是改良Kadish A期和B期患者总生存(OS)的独立预后因素(P=0.699和P=0.248)。卡迪什C期和D期患者行PORT治疗的OS明显优于未行PORT治疗的OS (P=0.03和P0.05)。结论:PORT改善了改良的卡迪什C期和D期ONB患者的生存结局。然而,PORT可能不会影响改良卡迪什A期和B期个体的生存。ONB不推荐化疗;因此,需要进一步的研究来确定其治疗意义。
{"title":"Survival impact of postoperative radiotherapy in patients with olfactory neuroblastoma: 513 cases from the SEER database.","authors":"G. Duo, Jilong Feng, E. Zhang, Li-jun Wang","doi":"10.21203/RS.3.RS-353943/V1","DOIUrl":"https://doi.org/10.21203/RS.3.RS-353943/V1","url":null,"abstract":"PUPOSE\u0000To evaluate the impact of postoperative radiotherapy (PORT) on survival in olfactory neuroblastoma (ONB) patients with different tumor staging.\u0000\u0000\u0000MATERIAL AND METHODS\u0000Patients with ONB were selected in the Surveillance, Epidemiology and End Results (SEER) database from 2004-2016. Survival analyses were performed using Kaplan-Meier (K-M) method, Cox regression analysis, and competing risk model.\u0000\u0000\u0000RESULTS\u0000A total of 513 patients were included in the study. Univariate and multivariate analysis results demonstrated that PORT was not an independent prognostic factor for overall survival (OS) of modified Kadish stage A and B patients (P=0.699 and P=0.248, respectively). Kadish stage C and D patients who underwent PORT had significantly better OS than those who did not undergo PORT (P=0.03 and P<0.0001). K-M curves revealed that the 5- and 10-year OS rates of patients who underwent PORT vs. non-PORT were 85.3% vs. 70.4% and 68.2% vs. 56.8% in stage C patients, respectively. For stage D patients, the 5-year OS rates were 70.7% and 42.6%, and 10-year OS rates were 53.4% and 29.5% in the PORT and non-PORT groups, respectively. The competitive risk model revealed that the 5-year cancer-specific cumulative mortality incidence decreased by 26.6% while the 10-year mortality incidence decreased by 41.4% in Kadish stage C patients who were treated using PORT; meanwhile, for Kadish stage D patients who were treated with PORT, the 5- and 10-year mortality incidences were reduced by 35.3% and 42.6%, respectively. Furthermore, we found that chemotherapy was not related to the prognosis of ONB patients (all P>0.05).\u0000\u0000\u0000CONCLUSION\u0000Our results indicate that PORT improved survival outcomes of modified Kadish stage C and D ONB patients. However, PORT may not affect survival for modified Kadish stage A and B individuals. Chemotherapy was not recommended for ONB; therefore, further studies are warranted to determine its therapeutic significance.","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"PP 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84268542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
期刊
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1